These Th2system cells release mediator cytokines IL-5 (driving mast cell activation) andIL-13 (causing mucus production) Furthermore, these neuropeptides stimulate the adjacent mast cells maintaining a continuous release of histamine from these cells
(4) Dou Y, Lee A, Zhu L, Morton J, Ladiges W
Injections 10 Min
If approved, we believe pemvidutide could offer an important option for obesity patients, including those with risk factors for cardiovascular disease. However, tolerability issues remain, as the trial led to one participant experiencing vomiting, and 4.1% of the patients in the drug cohort discontinuing treatment in the first 16 weeks, when compared to 2.1% in the placebo group
To realize their full therapeutic potential, future research must rigorously address several critical dimensions, which collectively form a roadmap for the field